经皮CT与MRI引导冷冻消融治疗cT1肾细胞癌:307例患者的中长期结局
本回顾性单中心研究评估307例病理证实的cT1肾细胞癌患者接受CT或MRI引导经皮冷冻消融的中长期结局,中位临床随访95个月。CT与MRI引导的总生存、无病生存及局部无进展生存均无显著差异,主要与次要技术有效率分别为96%和99%,总体不良事件率为14%。
要点
- cT1肾细胞癌经皮冷冻消融后10年总生存78%、疾病特异性生存99%、无病生存88%、局部无进展生存95%。
- CT与MRI引导的生存结局无显著差异,总生存HR 0.97(95%CI 0.57,1.67;P=.92)。
- 主要与次要技术有效率分别为96%和99%,总体不良事件率14%,包括11例3级和3例4级事件。
核心结论
- 经皮CT与MRI引导冷冻消融治疗cT1肾细胞癌具有相似的良好中长期结局。
研究设计与样本
- 符合HIPAA的回顾性单机构研究,纳入2000年8月至2017年7月接受经皮冷冻消融的307例病理证实孤立性cT1肾细胞癌患者。
- 肿瘤包括cT1a 282例、cT1b 25例,大小范围0.6-6.5 cm,中位大小2.5 cm;CT引导155例,MRI引导152例。
- 主要终点为总生存、疾病特异性生存、影像确认的无病生存和局部无进展生存,采用Kaplan-Meier分析;次要终点为技术有效率和不良事件率。
诊断标准与关键数值
- 3年、5年、10年、15年总生存分别为91%(95%CI 88%,94%)、86%(95%CI 82%,90%)、78%(95%CI 73%,84%)、76%(95%CI 69%,83%)。
- 3年、5年、10年、15年疾病特异性生存分别为99.6%(95%CI 99%,100%)、99%(95%CI 98%,100%)、99%(95%CI 98%,100%)、99%(95%CI 98%,100%)。
- 3年、5年、10年、15年无病生存分别为94%(95%CI 92%,97%)、91%(95%CI 88%,96%)、88%(95%CI 83%,93%)、88%(95%CI 83%,93%)。
- 3年、5年、10年、15年局部无进展生存分别为97%(95%CI 94%,99%)、95%(95%CI 93%,98%)、95%(95%CI 93%,98%)、95%(95%CI 93%,98%)。
- 主要技术有效率96%,次要技术有效率99%;总体不良事件率14%(43/307),包括11例3级事件和3例4级事件(依据常见不良事件评价标准)。
临床应用与阅片要点
- CT与MRI引导的cT1肾细胞癌冷冻消融在总生存、无病生存和局部无进展生存方面无显著差异,总生存HR 0.97(95%CI 0.57,1.67;P=.92),无病生存HR 0.63(95%CI 0.26,1.52;P=.30),局部无进展生存HR 0.83(95%CI 0.26,2.74;P=.77)。
- 中位临床随访95个月(范围8-219个月),中位影像随访41个月(范围0-189个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Percutaneous ablation for cT1 renal cell carcinoma (RCC) remains underused, partially because of heterogeneous and limited long-term outcomes data assessing recent cryoablation methods. Purpose To report intermediate- to long-term outcomes of image-guided percutaneous cryoablation of cT1 RCC and to compare outcomes for CT versus MRI guidance. Materials and Methods This HIPAA-compliant retrospective single-institution study assessed patients who underwent percutaneous cryoablation for solitary pathology-proven cT1 RCC between August 2000 and July 2017. Tumors (cT1a, n = 282; cT1b, n = 25; size range, 0.6-6.5 cm; median size, 2.5 cm) underwent cryoablation with CT (n = 155) or MRI (n = 152) guidance. Primary end points of overall survival (OS), disease-specific survival (DSS), imaging-confirmed disease-free survival (DFS), and local progression-free survival (LPFS) were calculated by using Kaplan-Meier analysis. Secondary end points of technique efficacy and adverse event rate were also calculated. Primary and secondary end points for CT and MRI guidance were compared by using univariable regression analysis. Results A total of 307 patients (mean age, 68 years ± 11 [standard deviation]; 192 men) were evaluated. Median clinical follow-up lasted 95 months (range, 8-219 months), and median imaging follow-up lasted 41 months (range, 0-189 months). Survival metrics at 3, 5, 10, and 15 years, respectively, included OS of 91% (95% confidence interval [CI]: 88%, 94%), 86% (95% CI: 82%, 90%), 78% (95% CI: 73%, 84%), and 76% (95% CI: 69%, 83%); DSS of 99.6% (95% CI: 99%, 100%), 99% (95% CI: 98%, 100%), 99% (95% CI: 98%, 100%), and 99% (95% CI: 98%, 100%); DFS of 94% (95% CI: 92%, 97%), 91% (95% CI: 88%, 96%), 88% (95% CI: 83%, 93%), and 88% (95% CI: 83%, 93%); and LPFS of 97% (95% CI: 94%, 99%), 95% (95% CI: 93%, 98%), 95% (95% CI: 93%, 98%), and 95% (95% CI: 93%, 98%). Survival did not significantly differ between CT and MRI guidance, with univariable Cox regression analysis hazard ratios of 0.97 (95% CI: 0.57, 1.67; P = .92) for OS, 0.63 (95% CI: 0.26, 1.52; P = .30) for DFS, and 0.83 (95% CI: 0.26, 2.74; P = .77) for LPFS. Primary and secondary technique efficacy were 96% and 99%, respectively. Overall adverse event rate was 14% (43 of 307), including 11 grade 3 events and three grade 4 events according to the Common Terminology Criteria for Adverse Events. Conclusion Percutaneous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma had similar excellent intermediate- and long-term outcomes. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Georgiades in this issue.
引用
- Bhagavatula SK, Tuncali K, Shyn PB, et al. Percutaneous CT- and MRI-guided Cryoablation of cT1 Renal Cell Carcinoma: Intermediate- to Long-term Outcomes in 307 Patients. Radiology. 2020. PMID: 32633677. doi:10.1148/radiol.2020200149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。